Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study

Tasnim Chaghtai, Christina Zill, Linda Dainese, Jenny Wegert, Savi Savola, Sergey Popov, William Mifsud, Gordan Vujanic, Neil Sebire, Yves Le Bouc, Peter F. Ambros, Leo Kager, Maureen J. O’Sullivan, Annick Blaise, Christophe Bergeron, Linda Holmqvist Mengelbier, David Gisselsson, Marcel Kool, Godelieve A.M. Tytgat, Marry M. van den Heuvel-Eibrink, Norbert Graf, Harm van Tinteren, Aurore Coulomb, Manfred Gisselsson, Richard Dafydd Williams, and Kathy Pritchard-Jones

Listen to the podcast by Dr Geoerger at www.jco.org/podcasts

ABSTRACT

Purpose
Wilms tumor (WT) is the most common pediatric renal tumor. Treatment planning under International Society of Paediatric Oncology (SIOP) protocols is based on staging and histologic assessment of response to preoperative chemotherapy. Despite high overall survival (OS), many relapses occur in patients without specific risk factors, and many successfully treated patients are exposed to treatments with significant risks of late effects. To investigate whether molecular biomarkers could improve risk stratification, we assessed 1q status and other potential copy number biomarkers in a large WT series.

Materials and Methods
WT nephrectomy samples from 586 SIOP WT 2001 patients were analyzed using a multiplex ligation-dependent probe amplification (MLPA) assay that measured the copy number of 1q and other regions of interest.

Results
One hundred sixty-seven (28%) of 586 WTs had 1q gain. Five-year event-free survival (EFS) was 75.0% in patients with 1q gain (95% CI, 82.0% to 95.3%) and 82.2% in patients without gain (95% CI, 85.0% to 91.4%). OS was 88.4% with gain (95% CI, 83.5% to 93.6%) and 94.4% without gain (95% CI, 92.1% to 96.7%). In univariable analysis, 1q gain was associated with poorer EFS (P = .001; hazard ratio, 2.16). The association of 1q gain with poorer EFS retained significance in multivariable analysis adjusted for 1p and 16q loss, sex, stage, age, and histologic risk group. Gain of 1q remained associated with poorer EFS in tumor subsets limited to either intermediate-risk localized disease or nonanaplastic localized disease. Other notable aberrations associated with poorer EFS included MYCN gain and TP53 loss.

Conclusion
Gain of 1q is a potentially valuable prognostic biomarker in WT, in addition to histologic response to preoperative chemotherapy and tumor stage.

INTRODUCTION

Wilms tumor (WT) is the most common childhood renal malignancy. Most patients are treated effectively, with approximately 90% achieving 5-year survival, but new approaches are needed to improve the outcome of the remainder, especially in cases of recurrence, where only approximately 50% will survive. More specific biomarkers for treatment stratification could also reduce the therapeutic burden on the successfully treated majority. Treatment planning is currently determined by clinical staging and histopathologic criteria. In countries that follow the protocols of the International Society of Paediatric Oncology (SIOP), patients with WT typically receive...
neoadjuvant chemotherapy, and the histopathology at nephrectomy is used to classify patients into risk groups. Tumors with diffuse anaplasia or that contain a high proportion of chemoresponse blastema (blastemal type) are regarded as high risk; epithelial, stromal, mixed, and regressive subtypes are classified as intermediate risk, and completely necrotic tumors are classified as low risk. Using this classification, the SIOP WT 2001 trial recently reported that doxorubicin can be safely omitted from the treatment of stage II to III intermediate-risk histology tumors, although it still adds benefit when patients have high-risk histology. However, high-risk tumors are relatively uncommon, and most relapses still occur in patients with localized (stage I to III) low- and intermediate-risk histology tumors. Therefore, there is a clinical need to improve the sensitivity and specificity of risk prediction in WT. The SIOP WT 2001 trial included, as a secondary aim, investigation of the potential value of including molecular biomarkers in addition to the current use of tumor stage and histology in risk stratification.

Previous analyses have identified multiple recurrent aberrations in WT. Notable genes with documented mutations include WT1, CTNNB1, WTX (AMERI), TP53, FBXW7, MYCN, SIX1/2, DICER1, DROSHA, and DGCGR8. Copy neutral loss of heterozygosity on 11p, common in stromal-type tumors, can lead to both second hit inactivation of mutated WT1 on 11p13 and aberrant expression of the imprinted genes H19 and IGF2 on 11p15; the latter locus is also frequently targeted by epigenetic aberrations.

Several WT genes, including WT1, WTX, TP53, FBXW7, and MYCN are also subject to recurrent copy number aberrations, as are a number of larger-scale genomic regions, but few of these are of known prognostic relevance. Simultaneous allele loss of 1p and 16q is associated with adverse outcome in patients with favorable-histology WT treated with immediate nephrectomy, and this biomarker is already used in treatment stratification by the Children’s Oncology Group of North America. We have recently shown that TP53 mutation and 17p loss, aberrations largely confined to anaplastic histology WT, are potential adverse indicators within this subtype. However, the utility of both these biomarkers is limited by their relative rarity. Genomic gain of 1q, one of the most common copy number changes in WT, seems to be associated with poor outcome, as is gain of MYCN. Recent studies in the United States and United Kingdom have focused on the significance of 1q gain and support its prognostic value.

The principal aim of this study was to assess the feasibility of using 1q gain as a prognostic biomarker by determining its association with event-free survival (EFS) and overall survival (OS) in a cohort drawn entirely from the SIOP WT 2001 clinical trial (which is, to our knowledge, the largest SIOP cohort so far analyzed for this biomarker). Accordingly, a rapid and relatively low-cost multiplex ligation-dependent probe amplification (MLPA) assay was developed and optimized to assess the copy number status of 1q and other key regions or gene-specific loci, including 1p, 16q, WT1, WTX, TP53, MYCN, and FBXW7.

MATERIALS AND METHODS

Patients

Patients registered prospectively in the SIOP WT 2001 clinical trial and treated with preoperative chemotherapy according to standardized risk-stratified regimens on the basis of tumor stage, histology, and metastatic response to preoperative chemotherapy, with stage I to IV WT and available frozen tumor were eligible for this study. Selection criteria and patient characteristics are provided in the Data Supplement (Methods). Informed consent was obtained from all families. Our research was approved by local ethics committees and conducted in accordance with the Helsinki Declaration.

Samples

All samples were freshly frozen specimens obtained at nephrectomy. Genomic DNA was prepared by standard methods. Only WT with a tumor content ≥ 50% as determined by a pediatric pathologist were used for this study (N = 586; Data Supplement Table S1). Full details, including sample inclusion criteria and DNA quality control (QC) metrics, are listed in the Data Supplement.

MLPA

The MLPA assay (P380-X2) was designed and developed in collaboration with MRC-Holland (Amsterdam, the Netherlands). The panel included 33 probes for regions or genes of interest, including seven on 1p, five on 1q, six on 16q, and three each targeting MYCN (2p), TP53 (17p), FBXW7 (4q), WT1 (11p), and WTX (AMERI, Xq), as well as reference and QC probes (Data Supplement Table S2). MLPA reactions were performed according to the manufacturer’s instructions, with appropriate internal quality and external normal controls. Polymerase chain reaction products were analyzed on an ABI 3730 DNA Analyzer, (Thermo Fisher Scientific, Waltham, MA).

Data Analysis

Copy number ratios relative to the normal reference were calculated with Cofalysyer.NET software (MRC-Holland) using the default settings. A numerical gain was scored when the ratios exceeded 1.2 and a loss when the ratios were lower than 0.8; all other values were considered to be normal diploid. For individual genes, aberrations were scored by the median ratio of the gene-specific probes. For 1p, 1q, and 16q, a gain or loss of at least two consecutive probed loci was required to score a chromosome arm aberration. Associations between copy number aberrations and histopathologic subtypes (Fig 1) were calculated by logistic regression, and survival analyses (Table 1; Fig 2; Data Supplement) were performed using the Kaplan-Meier estimator, log-rank test, and Cox proportional hazards regression model (Data Supplement Methods). For multivariable analyses, the factors considered are listed in the “Variable” column of Table 2.

RESULTS

Sample Series and Histologic Subtypes

A total of 586 patients with stages I to IV WTs, in which tumor content was confirmed by histologic review, high-quality DNA was successfully extracted, and data exceeded QC thresholds (Data Supplement Methods), were included in the analysis. In this series (Data Supplement Table S1), median clinical follow-up was 68 months, 92 patients had an event (relapse), and 41 patients died. In 55% of tumors (321 of 586), at least one of the major copy number aberrations targeted by the assay (1q gain, 1p loss, 16q loss, MYCN gain, TP53 loss, WT1 loss, WTX loss, or FBXW7 loss) was detected (Data Supplement Table S1). Overall, the numbers of alterations identified across all markers were consistent with previous reports. Some aberrations were more common in specific subtypes (Fig 1; Data Supplement Table S3) and some significant associations were noted. Compared with mixed-type histology, diffuse anaplasia was significantly associated with TP53 (17p) loss (P < .001), MYCN (2p) gain (P < .001), 16q loss (P < .001), and FBXW7 (4q) loss (P < .001), the latter presumably reflecting an
association between anaplasia and whole-arm 4q loss, which we have described previously.30 The stromal subtype was associated with WT1 (11p) loss (P = .0014), consistent with previous reports, and with a significantly lower frequency of 1q gain than the other subtypes (P = .00912). A gain of 1q was most frequent in blastemal-type tumors (Fig 1), but not to a statistically significant extent. We

| Table 1. Univariable Survival Analyses |
|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Patient Series  | Aberration      | No. of Patients | No. of Relapses | Event P | Event HR | 5-Year EFS | No. of Deaths | Death P | Death HR | 5-Year OS |
|-----------------|----------------|----------------|----------------|----------|-----------|------------|---------------|---------|----------|-----------|
| Unselected patients (N = 586) | 1q gain | 167 | 43 | .001 | 2.33 | 75 | 19 | .01 | 2.16 | 88.4 |
| 1q other | 419 | 49 | 88.2 | 22 | 94.4 |
| 1p loss | 49 | 11 | .17 | 1.55 | 77.9 | 5 | .38 | 1.52 | 89 |
| 1p other | 537 | 81 | 85 | 36 | 93 |
| 16q loss | 94 | 20 | .12 | 1.48 | 78.5 | 11 | .07 | 1.88 | 89.1 |
| 16q other | 492 | 72 | 85.5 | 30 | 93.3 |
| 1p and 16q loss | 16 | 3 | .76 | 1.22 | 81.2 | 0 | .27 | 0.01 | 100 |
| 1p and 16q other | 570 | 89 | 84.5 | 41 | 92.4 |
| TP53 (17p) loss | 44 | 19 | < .001 | 4.03 | 55.2 | 16 | < .001 | 9.80 | 63.7 |
| TP53 (17p) other | 542 | 73 | 86.7 | 25 | 94.9 |
| WT1 (11p) loss | 50 | 6 | .45 | 0.73 | 86.6 | 1 | .15 | 0.26 | 97.8 |
| WT1 (11p) other | 536 | 86 | 84.2 | 40 | 92.2 |
| WTX (Xq) loss | 93 | 10 | .13 | 0.61 | 91.4 | 2 | .04 | 0.26 | 97.8 |
| WTX (Xq) other | 493 | 82 | 83 | 39 | 91.6 |
| MYCN (2p) gain | 88 | 26 | < .001 | 2.45 | 71.2 | 14 | < .001 | 3.09 | 83.7 |
| MYCN (2p) other | 498 | 66 | 86.7 | 27 | 94.2 |
| MYCN (only) gain | 60 | 20 | < .001 | 2.72 | 67.9 | 12 | < .001 | 3.91 | 79.4 |
| MYCN (only) other | 526 | 72 | 86.3 | 29 | 94.2 |
| FBXW7 (4q) loss | 24 | 15 | < .001 | 6.58 | 38 | 10 | < .001 | 9.62 | 57.4 |
| FBXW7 (4q) other | 562 | 77 | 86.4 | 31 | 94 |
| IR stage I-III (n = 441) | 1q gain | 114 | 22 | .004 | 2.21 | 82.2 | 3 | .99 | 1.01 | 98 |
| 1q other | 327 | 29 | 91.3 | 8 | 97.3 |
| 1p loss | 34 | 6 | 2.71 | 1.61 | 83.7 | 1 | .88 | 1.17 | 97 |
| 1p other | 407 | 45 | 89.4 | 10 | 97.5 |
| 16q loss | 59 | 9 | .4 | 1.36 | 84.6 | 3 | .21 | 2.27 | 96.4 |
| 16q other | 382 | 42 | 89.5 | 8 | 97.6 |
| 1p and 16q loss | 13 | 2 | .69 | 1.33 | 84.6 | 0 | .56 | 0.01 | 100 |
| 1p and 16q other | 428 | 49 | 89 | 11 | 97.4 |
| TP53 (17p) loss | 19 | 6 | .004 | 3.23 | 67.4 | 3 | < .001 | 8.33 | 89.2 |
| TP53 (17p) other | 422 | 45 | 89.9 | 8 | 97.8 |
| WT1 (11p) loss | 42 | 5 | .94 | 1.03 | 86.3 | 0 | .29 | 0.00 | 100 |
| WT1 (11p) other | 399 | 46 | 89.2 | 11 | 97.2 |
| WTX (Xq) loss | 79 | 8 | .58 | 0.81 | 92.4 | 0 | .11 | 0.00 | 100 |
| WTX (Xq) other | 362 | 43 | 88.1 | 11 | 96.9 |
| MYCN (2p) gain | 61 | 14 | .003 | 2.49 | 78.2 | 4 | .03 | 3.50 | 93.4 |
| MYCN (2p) other | 380 | 37 | 90.7 | 7 | 98.1 |
| MYCN (only) gain | 42 | 11 | .001 | 2.86 | 75.7 | 4 | .002 | 5.49 | 90.3 |
| MYCN (only) other | 399 | 40 | 90.3 | 7 | 98.2 |
| FBXW7 (4q) loss | 13 | 6 | < .001 | 4.85 | 59.3 | 1 | .23 | 3.25 | 100 |
| FBXW7 (4q) other | 428 | 45 | 89.9 | 10 | 97.4 |
| Non-AH stage I-III (n = 482) | 1q gain | 131 | 26 | .001 | 2.34 | 81.4 | 6 | .1 | 2.48 | 95.7 |
| 1q other | 351 | 30 | 91.4 | 6 | 98.1 |
| 1p loss | 42 | 8 | .13 | 1.78 | 82 | 3 | .05 | 3.47 | 92.3 |
| 1p other | 440 | 48 | 89.3 | 9 | 97.9 |
| 16q loss | 64 | 9 | .59 | 1.22 | 85.7 | 2 | .8 | 1.22 | 98.4 |
| 16q other | 418 | 47 | 89 | 10 | 97.2 |
| 1p and 16q loss | 14 | 2 | .76 | 1.25 | 85.7 | 0 | .55 | 0.01 | 100 |
| 1p and 16q other | 468 | 54 | 88.7 | 12 | 97.3 |
| TP53 (17p) loss | 17 | 5 | .02 | 2.82 | 69.3 | 2 | .02 | 5.24 | 93.3 |
| TP53 (17p) other | 465 | 51 | 89.3 | 10 | 97.5 |
| WT1 (11p) loss | 45 | 5 | .9 | 0.94 | 87.4 | 0 | .27 | 0.00 | 100 |
| WT1 (11p) other | 437 | 51 | 88.7 | 12 | 97.1 |
| WTX (Xq) loss | 81 | 8 | .5 | 0.77 | 92.6 | 0 | .1 | 0.00 | 100 |
| WTX (Xq) other | 401 | 48 | 87.7 | 12 | 96.8 |
| MYCN (2p) gain | 63 | 14 | .01 | 2.30 | 78.9 | 4 | .04 | 3.23 | 93.4 |
| MYCN (2p) other | 419 | 42 | 90.1 | 8 | 98 |
| MYCN (only) gain | 43 | 11 | .002 | 2.68 | 76.2 | 4 | .003 | 5.10 | 90.3 |
| MYCN (only) other | 439 | 45 | 89.8 | 8 | 98.1 |
| FBXW7 (4q) loss | 13 | 6 | < .001 | 4.83 | 59.3 | 1 | .23 | 3.28 | 100 |
| FBXW7 (4q) other | 469 | 50 | 89.5 | 11 | 97.3 |

Abbreviations: AH, anaplastic histology; EFS, event-free survival; HR, hazard ratio; IR, intermediate risk; OS, overall survival.
also noted an association between the regressive type and a lower frequency of WTX (AMER1, Xq) loss. Most aberrations, including 1q gain, were somewhat less common in stage I than in higher stage tumors (Data Supplement Table S4).

Univariable Outcome Analysis of 1q Gain

In the complete series of 586 patients (Table 1; Figs 2A and 2B), 167 tumors (28.5%) had 1q gain. Five-year EFS in the 1q-gain group was 75.0% (95% CI, 68.5% to 82.0%) and 88.2% in the no-gain
Gain of 1q As a Prognostic Biomarker in Wilms Tumors

### Univariable Outcome Analysis of 1p Loss and 16q Loss

Neither 1p loss nor 16q loss, nor combined loss of 1p and 16q, considered as a single biomarker in a univariable Cox model, was significantly associated with EFS or OS in the entire tumor series at the $P = .05$ level (Data Supplement). This was also true for the subsets, with the single exception of a marginal association between 1p loss and poorer OS in nonanaplastic patients (Table 1; Data Supplement Figs S1, S2, and S3).

### Multivariable Outcome Analyses

In a multivariable outcome analysis including 1q gain, 1p loss, 16q loss, tumor stage and histologic risk group, sex, and age, 1q gain was significantly associated with poorer EFS (HR, 1.98; $P = .002$), but not OS (HR, 1.61; $P = .16$; Table 2). The only other independent factors of those assessed for adverse outcome in the full series ($N = 586$) were high-risk histology and stage IV disease. The significant independent association of 1q gain with adverse EFS but not OS persisted in the subsets of intermediate-risk histology, localized WT ($n = 440$; EFS HR, 1.92; $P = .04$) and non-anaplastic, localized WT ($n = 481$; EFS HR, 2.0; $P = .02$).

### Univariable Analysis of Gene-Specific Markers

The outcome data for the other markers covered by the assay were also analyzed on an exploratory basis (Table 1; Data Supplement Figs S4-S9). MYCN (2p) gain was significantly associated with poorer EFS and OS in the complete data set, in the localized disease intermediate-risk subset, and in the localized disease subset with anaplastic WTs excluded (Data Supplement Fig S4). Using a more specific definition of MYCN gain, MYCN-only gain (excluding from the MYCN-gain group those tumors in which the DYSF control probe on 2p was also gained, because gains at both loci were likely to be whole-arm gains), we saw higher HRs and lower $P$ values (Table 1; Data Supplement Fig S5). Similarly, TP53 (17p) loss was significantly associated with inferior EFS and OS in the complete series and, perhaps surprisingly, in both subsets, neither of which included diffuse anaplastic WTs (Table 1; Data Supplement Fig S6).

A third copy number change, loss of the FBXW7 locus on 4q, was significantly associated with poorer EFS and OS in the complete 586 tumor series, but only with poorer EFS in both
group (95% CI, 85.0% to 91.4%). The corresponding OS values were 88.4% (95% CI, 83.5% to 93.6%) and 94.4% (95% CI, 92.1% to 96.7%), respectively. At the alpha significance level of .05, univariable analyses using the Cox proportional hazards regression model showed that 1q gain was associated with poorer EFS (hazard ratio [HR], 1.98; $P = .002$) and OS (HR, 1.61; $P = .01$).

Because 1q gain as a potential biomarker would be of most value in optimizing risk stratification in localized tumors, we also considered two important subsets. The first consisted of 441 patients with localized disease (stage I to III), intermediate-risk histology tumors according to the SIOP classification. In univariable analysis (Table 1; Figs 2C and 2D), 1q gain was significantly associated with inferior EFS (HR = .004; HR, 2.21) but not OS ($P = .99$; HR, 1.01). The second subset was selected to allow direct comparison with the Children’s Oncology Group risk stratification. Among 482 patients with localized, nonanaplastic tumors (ie, excluding both diffuse and focal anaplastic but including blastemal-type WTs), 1q gain was associated with poorer EFS ($P = .001$; HR, 2.34) but not OS ($P = .1$; HR, 2.48; Table 1; Figs 2E and 2F).

### Table 2. Multivariable Survival Analyses

| Patient Series          | Variable         | Comparison | Event-Free Survival | Overall Survival |
|-------------------------|------------------|------------|---------------------|-----------------|
|                         |                  |            | $P$  | HR  | Lower | Upper | $P$  | HR  | Lower | Upper |
| Unselected patients ($n = 585$) | 1p loss | No loss | .96  | .98  | .5    | 1.91  | .45  | .67  | .24   | 1.89  |
|                         | 1q gain | No gain  | .002 | 1.98 | 1.27  | 3.07  | .16  | 1.61 | .83   | 3.15  |
|                         | 16q loss | No loss | .63  | 1.14 | 0.68  | 1.91  | .39  | 1.37 | .67   | 2.83  |
|                         | Female | Male    | .98  | 0.99 | 0.65  | 1.51  | .81  | 0.93 | 0.49  | 1.74  |
| Stage II stage I        | Stage I        | Stage I   | .43  | 1.27 | 0.71  | 2.27  | .06  | 3.13 | 0.96  | 10.26 |
| Stage III stage I       | Stage I        | Stage I   | .17  | 1.52 | 0.83  | 2.79  | .01  | 4.39 | 1.36  | 14.12 |
| Stage IV stage I        | Stage I        | Stage I   | <.001| 4.58 | 2.58  | 8.15  | <.001| 21.65| 6.93  | 67.66 |
| High risk               | Intermediate risk | .001 | 2.28 | 1.41 | 3.68  | <.001| 8.13 | 4.05  | 16.32 |
| Age                     | Per unit       |           | .06  | 1.01 | 1    | 1.01  | .48  | 1    | 0.99  | 1.01  |
| IR stage I-III ($n = 440$) | 1p loss | No loss | .97  | 1.02 | 0.41  | 2.5   | .84  | 0.81 | 0.1   | 6.74  |
|                         | 1q gain | No gain  | .04  | 1.92 | 1.05  | 3.51  | .44  | 0.56 | 0.13  | 2.42  |
|                         | 16q loss | No loss | .64  | 1.2  | 0.56  | 2.55  | .09  | 3.51 | 0.82  | 15.12 |
|                         | Female | Male    | .27  | 0.73 | 0.41  | 1.28  | .04  | 0.24 | 0.06  | 0.92  |
| Stage II stage I        | Stage I        | Stage I   | .76  | 1.11 | 0.57  | 2.18  | .13  | 3.25 | 0.71  | 14.82 |
| Stage III stage I       | Stage I        | Stage I   | .13  | 1.73 | 0.85  | 3.54  | .02  | 7.01 | 1.45  | 33.78 |
| Age                     | Per unit       |           | .32  | 1    | 1    | 1.01  | .71  | 1    | 0.99  | 1.02  |
| Non-AH stage I-III ($n = 481$) | 1p loss | No loss | .73  | 1.15 | 0.52  | 2.54  | .45  | 1.75 | 0.4   | 7.61  |
|                         | 1q gain | No gain  | .02  | 2    | 1.13  | 3.57  | .62  | 1.39 | 0.38  | 5.11  |
|                         | 16q loss | No loss | .96  | 0.98 | 0.46  | 2.06  | .77  | 1.27 | 0.26  | 6.29  |
|                         | Female | Male    | .33  | 0.77 | 0.45  | 1.31  | .04  | 0.24 | 0.06  | 0.93  |
| Stage II stage I        | Stage I        | Stage I   | .36  | 1.34 | 0.72  | 2.5   | .05  | 5.12 | 0.99  | 26.4  |
| Stage III stage I       | Stage I        | Stage I   | .26  | 1.51 | 0.74  | 3.08  | .06  | 5.58 | 0.91  | 34.08 |
| High risk               | Intermediate risk | .71  | 0.85 | 0.38  | 1.94  | .45  | 1.71 | 0.42  | 7     |
| Age                     | Per unit       |           | .11  | 1    | 1    | 1.01  | .53  | 1    | 0.99  | 1.02  |

Abbreviations: AH, anaplastic histology; HR, hazard ratio; IR, intermediate risk.

www.jco.org © 2016 by American Society of Clinical Oncology 3199
(A, C, E) Event-free (EFS) and (B, D, F) overall survival (OS) curves for (A, B) complete series, (C, D) intermediate-risk localized disease, and (E, F) non-anaplastic localized disease Wilms tumors, stratified by 1q status. AH, anaplastic histology.

Fig 2.
subsets (Table 1; Data Supplement Fig S7). No significant associations were noted between the copy number status of WT1 and outcome at the \( P = .05 \) significance level (Table 1; Data Supplement Fig S8). For WTX, there was no significant association with EFS, but improved OS was marginally associated with copy number loss in the complete series only (\( P = .04 \); Data Supplement Fig S9).

This is, to our knowledge, the first study to carry out a large-scale analysis of 1q copy number aberrations in WT sampled at nephrectomy after neoadjuvant chemotherapy according to the SIOP WT 2001 protocol. The clinical characteristics of the patient cohort were representative of the entire registered population who had received preoperative chemotherapy and presented with unilateral disease; 586 patients with stage I to IV WT, including all intermediate- and high-risk histologic subtypes, were analyzed. We found that 1q gain is significantly associated with poorer EFS and OS in univariable analyses, with HRs in excess of two-fold for relapse and death. These results are broadly consistent with those recently reported in a study of patients treated by immediate nephrectomy under Children’s Oncology Group protocols without preoperative chemotherapy and, although it is essential to assess 1q gain independently in cohorts treated under both regimens, it is encouraging to note that it seems to be a prognostically valuable marker regardless of treatment protocol. However, in our multivariable analysis of the SIOP data, which also considered 1p loss, 16q loss, sex, stage, age, and histologic risk group, 1q gain remained significantly associated only with EFS (HR, 1.98; \( P = .002 \)) and not OS (HR, 1.61; \( P = .16 \)). This lack of association with OS is perhaps not surprising, given the comparatively low number of deaths in the patient series (41, compared with 92 relapses), reflecting the relative success of second-line therapy.

Because just over half of all relapses occur in children with localized WT that are not of high-risk histology, we analyzed this subset of patients (n = 441) in which treatment intensification to reduce relapse risk would be clinically appropriate and feasible. Here, we found that 1q gain retained its independent prognostic significance for EFS (HR, 1.92; \( P = .04 \)) but not OS in multivariable analysis. Similar results (HR, 2.00; \( P = .02 \)) were obtained for localized anaplastic tumors (n = 481), excluding both diffuse and focal anaplastic WTs but retaining blastema type. This subset is comparable to the current North American definition of favorable histology for localized patients treated by immediate nephrectomy (where blastema type, which implies chemoresistance, cannot be defined).

In contrast to a previous report on immediate nephrectomy patients,\(^ {20} \) we did not find that the combination of 1p loss and 16q loss was prognostically significant in the SIOP series in the univariable or multivariable analyses. This was true for both EFS and OS, in the entire series, and in the anaplastic and intermediate-risk subsets. However, the size of our sample series (significantly smaller than the immediate nephrectomy cohort) meant that the current study did not have sufficient power to assess reliably the prognostic significance of relatively rare aberrations such as combined 1p and 16q loss, observed in only 16 patients (three of whom relapsed). We note also that any copy neutral loss of heterozygosity, another possible mechanism of allele loss at these loci, would not be detected by MLPA. A substantially larger series would be required to obtain definitive results for this rare combined marker in SIOP patients.

In a previous study,\(^ {18} \) we presented an analysis of MYCN copy number status that included 234 of the samples described in this study. Therefore, our observations are not independent, but the current expanded series should give a more reliable indication of the prognostic relevance of MYCN gain. As before, we note that MYCN gain seems to be a promising adverse prognostic indicator for WT, for both EFS and OS (Data Supplement Fig S4). We also analyzed the data using a more specific definition of gain (MYCN-only gain; Data Supplement Fig S5), excluding whole-arm gains. The adverse association with both EFS and OS was retained in all univariable analyses, but with lower \( P \) values and higher HRs throughout, perhaps suggesting that the type of genomic disruption that has given rise to MYCN gain, rather than the relative dose of MYCN with regard to the genomic baseline, is more prognostically relevant. A higher resolution (eg, single nucleotide polymorphism array) platform that allows precise delineation of the region of gain and distinguishes between focal events, such as those we described previously,\(^ {13} \) and larger segmental changes would allow us to address this question.

In a previous study we described an association between poor outcome and TP53 aberrations (typically point mutation coincident with whole-arm copy number loss of 17p) in diffuse anaplastic tumors.\(^ {21} \) Interestingly, TP53 (17p) loss in the current study was associated with poorer EFS and OS, even in the subsets that excluded anaplastic tumors. It is currently not known whether the nonanaplastic tumors with copy number loss at this locus also had TP53 mutations or whether these tumors had any unusual histologic features, such as nuclear unrest.\(^ {31} \)

Loss of the FBXW7 locus on 4q was significantly associated with poorer EFS and OS in the complete tumor series and with adverse EFS only in the subsets. In earlier studies, we reported focal homozygous loss and point mutation of FBXW7 in several intermediate-risk histology WTs,\(^ {13} \) as well as broader but typically single copy loss of 4q associated with anaplasia\(^ {30} \); the current assay does not distinguish between these types of aberrations.

Optimizing treatment to minimize the risk of long-term adverse effects without compromising EFS or OS is a principal aim of clinical research in WT. The previous SIOP randomized trial\(^ {5,6} \) showed that therapeutic intensity could be reduced in patients with localized intermediate-risk tumors without affecting OS, at the cost of a 4.4% reduction in EFS (95% CI, 0.4% to 9.3%). Because it is clearly desirable for patients to avoid even treatable relapses, further refinement of first-line therapy remains a priority, and novel biomarkers may provide the key data required to improve risk stratification and maximize EFS. In this study, we have shown that MLPA provides a rapid and effective means of determining the status of copy number aberrations associated with poorer EFS. The relatively high frequency of 1q gain makes this marker particularly attractive for potential use in risk stratification. However, any change in intensity on the basis of 1q status alone would affect a significant proportion of patients who have experienced a reasonably good EFS when treated with current therapies.
and where relapse is salvageable. Hence, the SIOP Renal Tumours Study Group considers it may be more appropriate to define risk groups for treatment stratification on the basis of several combined molecular biomarkers, taking account of our findings of the adverse significance of MYCN gain and TP53 loss and incorporating mutations in recently detected WT genes, some of which are reported to have prognostic significance. This requires a prospective clinical study powered to include tumor stage and histologic risk group, both individually significant in our multivariable analysis, alongside quantitative assessment of the volume of blastema that survives preoperative chemotherapy, a further potential prognostic factor. This prospective study will also incorporate multiple sampling of each WT to determine the extent of intratumoral heterogeneity of 1q gain and other biomarkers. It will register all patients with a newly diagnosed renal tumor and continue the risk stratification and treatment arms for localized WT used in the SIOP WT 2001 trial. The study will be known as UMBRELLA, and is expected to open in 2016.

REFERENCES

1. Breslow N, Olshan A, Beckwith J, et al: Epidemiology of Wilms tumor. Med Pediatr Oncol 21:172-181, 1993
2. Pritchard-Jones K, Moroz V, Vujanic G, et al: Treatment and outcome of Wilms’ tumour patients: An analysis of all cases registered in the UKW3 trial. Ann Oncol 23:2457-2463, 2012
3. Kalapurakal JA, Dorne JS, Perlman EJ, et al: Management of Wilms’ tumour: Current practice and future goals. Lancet Oncol 5:37-46, 2004
4. Vujanic GM, Sandstedt B, Harms D, et al: Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38:79-82, 2002
5. Pritchard-Jones K, Bergeron C, de Camargo B, et al: Omission of doxorubicin from the treatment of tumor locus on 11p13 defined by multiple CpG island-associated transcripts. Science 250:994-997, 1990
6. Call KM, Glazer T, Ito CY, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60:509-520, 1990
7. Gessler M, Poustka A, Cavenee W, et al: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774-778, 1990
8. Koesters R, Ridder R, Kopp-Schneider A, et al: Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res 59:3880-3882, 1999
9. Rivera MN, Kim WJ, Wells J, et al: An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 316:642-645, 2007
10. Bardeesy N, Falkoff D, Petruzzi MJ, et al: Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7:91-97, 1994
11. Williams RD, Al-Saadi R, Chagtai T, et al: Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms’ tumors. Clin Cancer Res 18:2036-2045, 2010
12. Rakheja D, Chen KS, Liu Y, et al: Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun 2:4802, 2014
13. Torrezan GT, Ferreira EN, Nakahata AM, et al: Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat Commun 5:4039, 2014
14. Walz AL, Ooms A, Gadd S, et al: Recurrent DGCGR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:298-311, 2015
15. Wegert J, Ishaque N, Vardapour R, et al: Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27:298-311, 2015
16. Williams RD, Chagtai T, Alcaide-German M, et al: Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget 6:7232-7243, 2015
17. Scott RH, Douglas J, Baskcomb L, et al: Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause non syndromic Wilms tumor. Nat Genet 40:1329-1334, 2008
18. Grundy PE, Breslow NE, Li S, et al: Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumour Study Group. J Clin Oncol 23:7312-7321, 2005
19. Maschietto M, Williams RD, Chagtai T, et al: TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS One 9:e109924, 2014
20. Hing S, Lu YJ, Summersgill B, et al: Gain of 1q is associated with adverse outcome in favorable histology Wilms’ tumors. Ann J Pathol 158:393-398, 2001
21. Lu YJ, Hing S, Williams R, et al: Chromosome 1q expression profiling and relapse in Wilms’ tumour. Lancet 360:385-386, 2002
22. Natraj R, Williams RD, Hing SN, et al: Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 210:49-56, 2006
23. Perotti D, Spreafico F, Tom F, et al: Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse. Genes Chromosomes Cancer 51:644-653, 2012
24. Segers H, van den Heuvel-Eibrink MM, Williams RD, et al: Gain of 1q is a marker of poor prognosis in Wilms’ tumors. Genes Chromosomes Cancer 52:1065-1074, 2013
25. Schouten JP, McElgunn CJ, Waijier R, et al: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57, 2002
26. Verheul H, Pritchard-Jones K: Treatment of Wilms tumour: The SIOP approach, in Pritchard-Jones K, Hill DA, Shear TD, Liu T, et al: Clinical and biologic significance of nuclear unrest in Wilms tumour. Berlin Heidelberg, Germany, Springer-Verlag, 2014, pp 101-118
27. Williams RD, Al Saadi R, Natrajan R, et al: Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer 50:962-995, 2011
28. Williams RD, Al-Saadi R, Natrajan R, et al: Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer 50:962-995, 2011
29. Chagtai et al: Omission of doxorubicin from the treatment of Wilms’ tumour. Lancet Oncol 5:37-46, 2004
30. van den Heuvel-Eibrink MM, van Tinteren H, Aurore Coulomb, Manfred Gessler, Richard Dafydd Williams, Kathy Pritchard-Jones
31. Collecton and assembly of data: Manfred Gessler, Richard Dafydd Williams, Kathy Pritchard-Jones, Anick Blaise, Marry M. van den Heuvel-Eibrink, Harm van Tinteren, Aurore Coulomb, Manfred Gessler, Richard Dafydd Williams, Kathy Pritchard-Jones
32. Manuscript writing: All authors
33. Final approval of manuscript: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at www.jco.org.

AUTHOR CONTRIBUTIONS

Conception and design: Tasnim Chagtai, Suvi Savola, Gordan Vujanic, David Gisselsson, Marry M. van den Heuvel-Eibrink, Norbert Graf, Harm van Tinteren, Aurore Coulomb, Manfred Gessler, Richard Dafydd Williams

Collection and assembly of data: All authors

Data analysis and interpretation: Tasnim Chagtai, Christina Zill, Linda Dainese, Jenny Wegert, Gordan Vujanic, Yves Le Bouc, Peter F. Ambros, Annick Blaise, Marry M. van den Heuvel-Eibrink, Harm van Tinteren, Aurore Coulomb, Manfred Gessler, Richard Dafydd Williams, Kathy Pritchard-Jones

Manuscript writing: All authors

Final approval of manuscript: All authors

© 2016 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY
Gain of 1q As a Prognostic Biomarker in Wilms Tumors

Affiliations

Tasnim Chagtai, William Mifsud, Neil Sebire, Richard Dafydd Williams, and Kathy Pritchard-Jones, University College London Institute of Child Health, London; Sergey Popov, University Hospital of Wales; Gordan Vujanić, Cardiff University School of Medicine, Cardiff, United Kingdom; Christina Zill, Jenny Wegert, and Manfred Gessler, Wuerzburg University, Wuerzburg; Marcel Kool, German Cancer Research Center, Heidelberg; Norbert Graf, Saarland University Hospital, Homburg, Germany; Linda Dainese, Yves Le Bouc, Annick Blaise, and Aurore Coulomb, Sorbonne Universités; Linda Dainese, Yves Le Bouc, and Aurore Coulomb, Assistance Publique Hôpitaux de Paris–Hôpital Armand Trousseau, Paris; Christophe Bergeron, Centre Léon Bérard, Lyon, France; Suvi Savola, MRC-Holland; Harm van Tinteren, Netherlands Cancer Institute, Amsterdam; Godelieve A.M. Tytgat and Marry M. van den Heuvel-Eibrink, Princess Maxima Center for Pediatric Oncology/Hematology, Utrecht, the Netherlands; Peter F. Ambros and Leo Kager, Children's Cancer Research Institute; Leo Kager, St Anna Children’s Hospital, Vienna, Austria; Maureen J. O’Sullivan, Our Lady’s Children’s Hospital, Dublin, Ireland; and Linda Holmquist Mengelbier and David Gisselsson, Lund University, Lund, Sweden.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Tasnim Chagtai
No relationship to disclose

Christina Zill
Employment: Roche Diagnostics Deutschland
Honoraria: Roche Diagnostics Deutschland
Travel, Accommodations, Expenses: Roche Diagnostics Deutschland

Linda Dainese
No relationship to disclose

Jenny Wegert
No relationship to disclose

Suvi Savola
Employment: MRC-Holland

Sergey Popov
No relationship to disclose

William Mifsud
No relationship to disclose

Gordan Vujanić
No relationship to disclose

Neil Sebire
No relationship to disclose

Yves Le Bouc
Honoraria: Ipsen, Sandoz
Consulting or Advisory Role: Sandoz
Speakers’ Bureau: Ipsen
Research Funding: Sandoz (Inst)

Peter F. Ambros
No relationship to disclose

Leo Kager
Travel, Accommodations, Expenses: Novartis

Maureen J. O'Sullivan
No relationship to disclose

Annick Blaise
No relationship to disclose

Christophe Bergeron
No relationship to disclose

Linda Holmquist Mengelbier
No relationship to disclose

David Gisselsson
Consulting or Advisory Role: Spago Nanomedical

Marcel Kool
No relationship to disclose

Godelieve A.M. Tytgat
No relationship to disclose

Marry M. van den Heuvel-Eibrink
No relationship to disclose

Norbert Graf
No relationship to disclose

Harm van Tinteren
No relationship to disclose

Aurore Coulomb
No relationship to disclose

Manfred Gessler
No relationship to disclose

Richard Dafydd Williams
No relationship to disclose

Kathy Pritchard-Jones
No relationship to disclose
Acknowledgment

We thank all the families who donated samples and all the staff at the treatment centers in the United Kingdom, Republic of Ireland, Germany, Austria, France, the Netherlands, and Sweden who enrolled patients in the SIOP WT 2001 trial and study and collected frozen tumor for the biologic studies. This study builds on the work of Jan de Kraker, MD, original chief investigator of the SIOP WT 2001 trial, who died on January 19, 2012. We thank Rebecca West and Nelly Bier for technical assistance, and Mariana Maschietto for helpful comments during the development of this study. The United Kingdom clinical database was managed by the Children's Cancer Trials Team, Cancer Research UK Clinical Trials Unit, Birmingham. Samples were made available by individual treatment centers, in the United Kingdom by the Children’s Cancer and Leukaemia Group, and in France by the French Pediatric Renal Tumor Pathology Group, Cardiobiotec, Tumorothèque Marseille, Service de Pathologie Robert-Debré Assistance Publique Hôpitaux de Paris–Université Denis-Diderot Paris 7–Sorbonne Paris Cité, Tumorothèque Necker–Enfants malades, Centre de Ressources Biologiques (CRB) Paris Sud, Tumorothèque Champagne-Ardenne, Tumorothèque Caen Basse-Normandie, Tumorothèque Régionale Franche Comté, CRB Grenoble, Tumorothèque Lille–Centre Régional de Référence en Cancérologie, Tumorothèque du Limousin, and CRB Hôpitaux Universitaires de Strasbourg.